Val-Cit-PABC-DOX 

Val-Cit-PABC-DOX (compound 10109), an epsilon-poly-L-lysine-based drug conjugate, is an agent-linker conjugate for ADC by using a DNA topoisomerase I and topoisomerase II inhibitor, Doxorubicin (HY-15142), linked via the linker, Val-Cit-PABC^[1].

Antibody-drug conjugates (ADCs) carry a highly potent small-molecule toxin covalently connected on the antibody via a proper linker. For therapeutic ADCs in cancer treatment, the antibody targets specific antigen of tumor cell surface with high binding affinity, thereafter the intact ADC was internalized into the tumor cells with the antigen and digested in the lysosome to release the antitumor toxin^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

948.97

C₄₆H₅₆N₆O₁₆

1022094-34-3

Solid

Orange to red

OC1=C(C(C2=CC=CC(OC)=C2C3=O)=O)C3=C(O)C4=C1C[C@](C(CO)=O)(O)C[C@@H]4O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)NC(OCC6=CC=C(C=C6)NC([C@H](CCCNC(N)=O)NC([C@@H](N)C(C)C)=O)=O)=O

Room temperature in continental US; may vary elsewhere.

-20°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

• [1]. Furao Zhang, et al. Epsilon-poly-l-lysine-based drug conjugate, intermediate thereof, and application thereof. WO2023078464A1.